跳至主要内容
临床试验/EUCTR2005-000622-23-IT
EUCTR2005-000622-23-IT进行中(未招募)不适用

A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of AGRIPPAL? S1 Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2005-2006, when Administered to Non-Elderly Adult and Elderly Subjects

CHIRO0 个研究点开始时间: 2007年8月7日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 未提供

研究者

发起方
CHIRO

相似试验

进行中(未招募)
不适用
A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of FLUAD Surface Antigen, Inactivated, Adjuvanted with MF59C.1 Influenza Vaccine, Formulation 2010-2011, when Administered to Elderly Subjects - NDInfluenza poses a significant threat to individual and public health, and influenza vaccination with a trivalent inactivated influenza vaccine is widely recommended to children, adults at risks and elderly. Due to antigenic changes of influenza viruses, the virus strains used in interpandemic influenza vaccines are adjusted every year according to WHO (World Health Organization) and CHMP (Committee for Medicinal Products for Human Use) recommendations.MedDRA version: 9.1Level: LLTClassification code 10059430
EUCTR2010-018603-29-ITOVARTIS VACCINES AND DIAGNOSTICS S.R.L.
进行中(未招募)
不适用
A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of AGRIPPAL S1 Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2010-2011, when Administered to Non-elderly Adult and Elderly Subjects - NDInfluenza poses a significant threat to individual and public health, and influenza vaccination with a trivalent inactivated influenza vaccine is widely recommended to children, adults at risks and elderly. Due to antigenic changes of influenza viruses, the virus strains used in interpandemic influenza vaccines are adjusted every year according to WHO (World Health Organization) and CHMP (Committee for Medicinal Products for Human Use) recommendations.MedDRA version: 9.1Level: LLTClassification code 10059430
EUCTR2010-018583-17-ITOVARTIS VACCINES AND DIAGNOSTICS S.R.L.
进行中(未招募)
1 期
A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of AGRIPPAL S1® Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2007-2008, when Administered to Non-Elderly Adult and Elderly Subjects - Agrippal seasonal trialProphylaxis of Influenza
EUCTR2007-000963-28-GBovartis Vaccines and Diagnostics S.r.l126
进行中(未招募)
不适用
A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of FLUAD Surface Antigen, Inactivated, (Adjuvanted with MF59C.1) Influenza Vaccine, Formulation 2006-2007, when Administered to Elderly Subjects - NDActive influenza immunoprofilaxisMedDRA version: 9.1Level: SOCClassification code 10021881Term: Infections and infestations
EUCTR2006-000610-20-ITCHIRO
进行中(未招募)
不适用
A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of FLUAD? Surface Antigen, Inactivated, (Adjuvanted with MF59C.1) Influenza Vaccine, Formulation 2005-2006, when Administered to Elderly Subjects
EUCTR2005-000621-38-ITCHIRO